Suppr超能文献

多中心研究:在光子放疗后,对头颈部恶性肿瘤进行碳离子再放疗。

Multicenter study of re-irradiation using carbon-ions for head and neck malignancies after photon radiotherapy.

机构信息

Department of Radiology, Hyogo Ion Beam Medical Center, Tatsuno, Japan.

Department of Radiation Oncology, Hyogo Ion Beam Medical Center Kobe Proton Center, Kobe, Japan.

出版信息

Cancer Med. 2022 Oct;11(19):3593-3601. doi: 10.1002/cam4.4741. Epub 2022 Apr 7.

Abstract

PURPOSE

The goal of this multicenter retrospective study of patients with head and neck malignancies was to evaluate the efficacy and safety of carbon-ion (C-ion) radiotherapy (RT) after photon RT.

METHODS

We enrolled 56 patients with head and neck malignancies who underwent re-irradiation (re-RT) using C-ions between November 2003 and March 2019, treated previously with photon RT. The tumors at re-RT were located in the sinonasal cavities (n = 20, 35.7%), skull base (n = 12, 21.4%), and orbit (n = 7, 12.5%). The tumors at the initial RT were located in the sinonasal cavities (n = 13, 23.2%), skull base (n = 9, 16.1%), and orbit (n = 9, 16.1%). The median period between the initial RT and re-RT was 41 (4-568) months. The most common histology of re-RT was squamous cell carcinoma (n = 11, 19.6%). The most commonly used protocol was 57.6 Gy (relative biological effectiveness) in 16 fractions (n = 23, 41.1%). Surgery preceded re-RT in three patients (5.4%). One patient with malignant melanoma received concurrent chemotherapy.

RESULTS

The 2-year local control, progression-free survival, and overall survival rates were 66.5%, 36.9%, and 67.9%, respectively. The median follow-up time was 28 months. Two patients (3.6%) developed grade ≥ 3 acute toxicities, and 14 (25.0%) developed grade ≥ 3 late toxicities. A single patient had confirmed grade 5 dermatitis with infection.

CONCLUSION

Re-RT using C-ions for head and neck malignancies after photon RT is an effective treatment with tolerable toxicity.

摘要

目的

本项多中心回顾性研究纳入了 56 例头颈部恶性肿瘤患者,这些患者在先前接受光子放射治疗(RT)后,采用碳离子(C 离子)再次进行放射治疗(re-RT),旨在评估 C 离子 RT 的疗效和安全性。

方法

我们纳入了 56 例先前接受光子 RT 治疗后,再次采用 C 离子进行 re-RT 的头颈部恶性肿瘤患者。在 re-RT 时,肿瘤位于鼻腔鼻窦(n=20,35.7%)、颅底(n=12,21.4%)和眼眶(n=7,12.5%)。在初始 RT 时,肿瘤位于鼻腔鼻窦(n=13,23.2%)、颅底(n=9,16.1%)和眼眶(n=9,16.1%)。初始 RT 与 re-RT 之间的中位时间为 41(4-568)个月。re-RT 最常见的组织学类型是鳞状细胞癌(n=11,19.6%)。最常使用的方案是 57.6 Gy(相对生物效应),16 次分割(n=23,41.1%)。3 例患者(5.4%)在 re-RT 前行手术。1 例恶性黑色素瘤患者接受了同期化疗。

结果

2 年局部控制率、无进展生存率和总生存率分别为 66.5%、36.9%和 67.9%。中位随访时间为 28 个月。2 例患者(3.6%)发生 3 级及以上急性毒性,14 例患者(25.0%)发生 3 级及以上晚期毒性。1 例患者发生了确诊的 5 级放射性皮炎伴感染。

结论

光子 RT 后采用 C 离子再次进行头颈部恶性肿瘤的 re-RT 是一种有效且毒性可耐受的治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ae7/9554451/1044d910bef6/CAM4-11-3593-g003.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验